|Bid||198.00 x 800|
|Ask||199.00 x 1300|
|Day's range||194.51 - 204.84|
|52-week range||54.21 - 227.71|
|Beta (5Y monthly)||1.47|
|PE ratio (TTM)||133.51|
|Earnings date||03 Aug 2021 - 09 Aug 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||181.17|
Covid jabs for billions of humans will earn their makers billions of dollars. We look at the drug firms – led by Pfizer and Moderna – that are set to profit most in an unprecedented global vaccination drive
When they did -- thanks to Pfizer, BioNTech, and Moderna -- the results were much better than most had hoped for. The Pfizer-BioNTech drug -- now marketed as Comirnaty -- was the first to share phase 3 data. Moderna followed two weeks later with its own impressive results.
It hasn't been a secret that the COVID-19 vaccines developed by Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) are highly effective. In this Motley Fool Live video recorded on June 9, Motley Fool contributors Keith Speights and Brian Orelli discuss what investors should make of the latest CDC data.